Waseem Akhtar Shamshari
Posters-Accepted Abstracts: Metabolomics
Diabetes mellitus is the second most dangerous non-communicable disease after cancer. Scientists around the globe try to hunt a cost effective and permanent treatment of this deadly malady. The recent trend is to control the disease by targeting the enzymes/proteins with inhibitors. Secreted frizzled-related protein 4 (SFRP4) is found to arouse five folds more risk of diabetes in patients when its expression is up-regulated. This study was designed to find out potential inhibitors of SFRP4. SFRP4 was analyzed by bioinformatics tools (sequence tool, structure tool and docking tools). The assessment of SFRP4 was done by PROCHECK, ERRAT, Ramachandran and VERIFY-3D to add confidence in its analysis. Three inhibitors namely cyclothiazide, clopamide and perindopril were found to have strong affinity for catalytic site residues (Pro120, Gln60, Tyr61, and Tyr81) of SFRP4 which results in down regulation of SFRP4 expression. These inhibitors showed significant interactions with SFRP4 as compared to other inhibitors as well as with control (acetohexamide) that have binding affinity with Gln60, Tyr61, Tyr81 residues. The findings suggest the possible hope for the treatment of diabetes mellitus type 2 by inhibiting the SFRP4.
Metabolomics:Open Access received 799 citations as per Google Scholar report